Enliven Therapeutics, Inc. · NASDAQ:ELVN

Hohl Benjamin sold 6,018 Enliven Therapeutics, Inc. shares (Form 4)

Traded Jul 17, 2026 · Filed Jul 21, 2026

On Jul 17, 2026, Hohl Benjamin (CHIEF FINANCIAL OFFICER) sold 6,018 Enliven Therapeutics, Inc. shares at an average US$52.64 for US$317K under a trading plan, leaving 46,054 shares. Filed Jul 21, 2026 (Form 4).

Sold
6,018 shares
Price
US$52.64 average (US$49.97 to US$53.87)
Value
US$317K
Holding after
46,054 shares
Trading plan
Yes (Made under a plan set in advance)
Role
CHIEF FINANCIAL OFFICER

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jul 17, 2026Common StockOption exercise1,072US$2.4852,072Direct
Jul 17, 2026Common StockSale324US$49.9751,748Direct
Jul 17, 2026Common StockSale369US$51.4851,379Direct
Jul 17, 2026Common StockSale2,564US$52.3248,815Direct
Jul 17, 2026Common StockSale2,638US$53.3846,177Direct
Jul 17, 2026Common StockSale123US$53.8746,054Direct

Source

View original at SEC

Related